Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 5/20 | 0.77 |
| ▸ | EDNRA | P25101 | 4/20 | 0.77 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.52 |
| ▸ | ACHE | P22303 | 5/20 | 0.47 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.46 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.44 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6540303 | 0.96 | AGTR1 (0.77) | AGTR1EDNRAAGTR2ACHELTB4R2 | |
| SCHEMBL6540973 | 0.95 | AGTR1 (0.75) | AGTR1EDNRAAGTR2ACHELTB4R2 | |
| SCHEMBL6540215 | 0.93 | AGTR1 (0.77) | AGTR1EDNRAAGTR2ACHELTB4R2 | |
| SCHEMBL6540813 | 0.91 | EDNRA (0.80) | AGTR1EDNRAAGTR2ACHELTB4R2 | |
| SCHEMBL6539684 | 0.91 | EDNRA (0.89) | AGTR1EDNRAAGTR2ACHELTB4R2 | |
| SCHEMBL6540548 | 0.91 | AGTR1 (0.81) | AGTR1EDNRAAGTR2ACHELTB4R2 | |
| SCHEMBL6539504 | 0.91 | EDNRA (0.81) | AGTR1EDNRAAGTR2ACHELTB4R2 | |
| SCHEMBL25084341 | 0.90 | AGTR1 (0.81) | AGTR1EDNRAAGTR2ACHELTB4R2 | |
| SCHEMBL29706543 | 0.90 | EDNRA (0.87) | AGTR1EDNRAAGTR2ACHELTB4R2 | |
| SCHEMBL30844555 | 0.90 | AGTR1 (0.81) | AGTR1EDNRAAGTR2ACHELTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-07-01 | — | — | US | claimed |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2002-10-03 | — | — | US | claimed |
| EP-1094816-A4 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2001-12-19 | — | — | EP | claimed |
| EP-1094816-A1 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-05-02 | — | — | EP | claimed |
| WO-2000001389-A1 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB CO. (US) | 2000-01-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | AGTR1 4/4885EDNRA 3/4885AGTR2 2/4885 |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | AGTR1 4/4885EDNRA 3/4885AGTR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.